GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo International PLC (OTCPK:ENDPQ) » Definitions » EV-to-EBITDA

Endo International (Endo International) EV-to-EBITDA : 0.37 (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Endo International EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Endo International's enterprise value is $-773 Mil. Endo International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-2,084 Mil. Therefore, Endo International's EV-to-EBITDA for today is 0.37.

The historical rank and industry rank for Endo International's EV-to-EBITDA or its related term are showing as below:

ENDPQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -838.28   Med: 8.25   Max: 63.45
Current: 0.37

During the past 13 years, the highest EV-to-EBITDA of Endo International was 63.45. The lowest was -838.28. And the median was 8.25.

ENDPQ's EV-to-EBITDA is ranked better than
98.44% of 707 companies
in the Drug Manufacturers industry
Industry Median: 14.03 vs ENDPQ: 0.37

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Endo International's stock price is $0.0006. Endo International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.410. Therefore, Endo International's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Endo International EV-to-EBITDA Historical Data

The historical data trend for Endo International's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo International EV-to-EBITDA Chart

Endo International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.99 8.59 16.21 0.46 0.37

Endo International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.39 1.74 63.44 0.37

Competitive Comparison of Endo International's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Endo International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endo International's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Endo International's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Endo International's EV-to-EBITDA falls into.



Endo International EV-to-EBITDA Calculation

Endo International's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-772.690/-2084.485
=0.37

Endo International's current Enterprise Value is $-773 Mil.
Endo International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2,084 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endo International  (OTCPK:ENDPQ) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Endo International's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0006/-10.410
=At Loss

Endo International's share price for today is $0.0006.
Endo International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.410.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Endo International EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Endo International's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Endo International (Endo International) Business Description

Traded in Other Exchanges
Address
Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4
Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.
Executives
James Patrick Tursi officer: Executive VP, Global R&D 106 ASHLEY COURT, MOORESTOWN NJ 08057
Frank B. Raciti officer: VP, Controller and CAO C/O ENDO HEALTH SOLUTIONS INC., 1400 ATWATER DRIVE, MALVERN PA 19355
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
William P Montague director
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
George Apostol officer: EVP, Head of Global R&D C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN 4 L2 00000
Mary Christine Smith director 3658 50TH AVE NE, SEATTLE WA 98105
Mark T. Bradley officer: EVP, Chief Financial Officer C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Mark G Barberio director 19 WIK STREET, WILLIAMSVILLE NY 14221
Jack D. Boyle officer: SVP, Interim Controller C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Roger H Kimmel director LATHAM & WATKINS, 885 THIRD AVENUE, NEW YORK NY 10022
Domenico Ciarico officer: EVP & Chief Commercial Officer C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Rahul Garella officer: EVP, Intl Pharmaceuticals C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Carrie Ann Nichol officer: VP, Controller & CAO 927 GRANDVIEW DRIVE, EXTON PA 19341